Filing Analysis
Monogram Technologies Inc. has completed its merger with a subsidiary of Zimmer Biomet Holdings, Inc., resulting in the company becoming a wholly-owned subsidiary of Zimmer Biomet. As part of this transaction, Monogram's common stock is being delisted from Nasdaq and shareholders are receiving cash plus contingent value rights (CVRs).
🚩 Red Flags
- Delisting of common stock from Nasdaq.
- Complete change in control and cessation of existing board/management.
- Termination of SEC reporting obligations (Form 15 filing planned).
📋 Key Facts
- Merger completed on October 7, 2025.
- Common stockholders receive $4.04 per share in cash plus one CVR per share.
- Series E Preferred Stock holders receive $100.00 per share in cash.
- CVRs include five milestones: proof-of-concept (Jan 2026), FDA 510(k) clearance, and three revenue milestones ($156M, $381M, and $609M) through 2030.
- The company has requested Nasdaq to suspend trading and delist the common stock via Form 25.
- All previous directors (Benjamin Sexson, Dr. Douglas Unis, Rick Van Kirk, Colleen Gray, Paul Riss) have ceased their roles.
Monogram Technologies Inc. announced that stockholders approved the merger agreement with Zimmer Biomet Holdings, Inc. at a special meeting held on September 30, 2025. The company expects to consummate the merger in the second half of 2025, subject to customary closing conditions and regulatory approvals.
🚩 Red Flags
- Risk factors include potential failure to obtain regulatory approvals or achieve revenue milestones for contingent value rights (CVRs).
📋 Key Facts
- Stockholders approved the Merger Proposal with approximately 63.95% affirmative vote (25,982,633 votes for).
- The merger involves Zimmer Biomet Holdings, Inc. via its subsidiary Honey Badger Merger Sub, Inc.
- A quorum of 26,924,769 shares was represented at the meeting.
- The transaction is expected to close in the second half of 2025.
- Closing remains subject to Hart-Scott-Rodino Antitrust Improvements Act waiting periods and other customary conditions.
Monogram Technologies Inc. announced that Zimmer Biomet has voluntarily withdrawn and resubmitted its HSR Act pre-merger notification to allow for additional FTC review time. The merger is expected to close in the second half of 2025, subject to customary closing conditions.
🚩 Red Flags
- Regulatory delay: The need for additional FTC review time indicates potential antitrust scrutiny or a desire to avoid a second request for information.
- Closing uncertainty: Completion is subject to shareholder approval and regulatory clearance in the second half of 2025.
📋 Key Facts
- Zimmer Biomet withdrew its HSR Act Notification and Report Form on September 4, 2025, to provide additional time for FTC review.
- A new 30-day waiting period has commenced, which is expected to expire on October 6, 2025.
- The merger would result in Monogram becoming a wholly owned subsidiary of Zimmer Biomet.
- The transaction was originally announced via an Agreement and Plan of Merger dated July 11, 2025.
Monogram Technologies Inc. has commenced a stockholder solicitation via text and email to encourage approval of its acquisition by Zimmer Biomet Holdings, Inc. This follows an initial announcement of the deal on July 14, 2025.
📋 Key Facts
- The company is soliciting votes for a 2025 special meeting of stockholders.
- The purpose of the meeting is to approve the acquisition by Zimmer Biomet Holdings, Inc.
- Solicitation methods include texts and emails sent to both registered and street holders.
- The acquisition was previously announced on July 14, 2025.
Monogram Technologies Inc. entered into a First Amendment to its existing Merger Agreement with Zimmer Biomet Holdings, Inc. The amendment was made in response to verbal comments from the SEC regarding the definition of 'Permitted Transfer' within the Contingent Value Rights (CVR) Agreement.
🚩 Red Flags
- SEC verbal comments regarding merger documentation can sometimes indicate complexities or potential issues with how value/transfers are structured in CVRs
📋 Key Facts
- Amendment dated August 27, 2025
- The amendment addresses a verbal comment from the SEC
- Specifically amends the definition of 'Permitted Transfer' in the Form of CVR Agreement (Exhibit B)
- The transaction involves Zimmer Biomet Holdings, Inc. as the Parent company
- Monogram is an emerging growth company
Monogram Technologies Inc. issued a text message to stockholders providing guidance and FAQs regarding the previously announced proposed acquisition by Zimmer Biomet Holdings, Inc.
📋 Key Facts
- The company sent a text message to stockholders on July 31, 2025.
- The communication directs stockholders to the FAQ section on the Company's Investor Relations page.
- The communication pertains to the proposed acquisition by Zimmer Biomet Holdings, Inc. announced on July 14, 2025.
Monogram Technologies Inc. issued a communication to stockholders regarding an ongoing proposed acquisition by Zimmer Biomet Holdings, Inc. The filing directs investors to updated FAQs on the company's website concerning the transaction announced on July 14, 2025.
📋 Key Facts
- The company sent an email to stockholders on July 30, 2025.
- The communication pertains to a proposed acquisition by Zimmer Biomet Holdings, Inc. previously announced on July 14, 2025.
- Stockholders are directed to the Investor Relations page for Frequently Asked Questions (FAQs) regarding the deal.
Monogram Technologies Inc. announced the performance of the world's first fully autonomous saw-based robotic knee replacement surgery using its mBôs™ TKA System at Krishna Shalby Hospital in India.
🚩 Red Flags
- Forward-looking statements include risks regarding lack of profitability and the need for additional capital to grow business.
📋 Key Facts
- Performed the world’s first fully autonomous saw-based robotic knee replacement surgery.
- Procedure utilized the Company’s proprietary mBôs™ TKA System.
- Surgery was performed at Krishna Shalby Hospital in Ahmedabad, India.
- The announcement was made via a press release under Regulation FD disclosure.
Monogram Technologies Inc. issued FAQs to stockholders regarding a proposed acquisition by Zimmer Biomet Holdings, Inc., originally announced on July 14, 2025.
📋 Key Facts
- Proposed acquisition of Monogram Technologies Inc. by Zimmer Biomet Holdings, Inc.
- Initial announcement of the acquisition occurred on July 14, 2025.
- The company provided supplemental FAQ information to stockholders via Item 7.01 disclosure on July 28, 2025.
Monogram Technologies Inc. has terminated its long-standing exclusive license agreement with the Icahn School of Medicine at Mount Sinai, resulting in the loss of rights to key intellectual property. To settle the termination, the company is paying $4 million via $500,000 in cash and the issuance of 35,000 shares of newly created Series E Redeemable Perpetual Preferred Stock.
🚩 Red Flags
- Loss of core intellectual property rights (reversion to licensor).
- Significant cash outflow ($500k) and equity dilution via high-liquidation preference preferred stock.
- Series E Preferred Stock has a $100/share liquidation preference, which is highly dilutive in a downside scenario for common shareholders.
- Mandatory redemption clauses create potential future liquidity strain if the company successfully raises capital.
📋 Key Facts
- Termination of Exclusive License Agreement with Mount Sinai effective July 10, 2025.
- All rights, title, and interest in licensed intellectual property revert to Mount Sinai.
- Total termination payment: $4,000,000.
- Payment structure: $500,000 cash and 35,000 shares of Series E Preferred Stock (liquidation preference of $100/share).
- Series E Preferred Stock is non-voting but carries a 10% cumulative dividend starting July 1, 2026.
- Redemption triggers: The company must redeem Series E stock if it raises >$25M in gross proceeds or if an entity acquires 40% voting power; partial redemption required if raising $10M-$25M.
Monogram Technologies Inc. has entered into a definitive agreement to be acquired by Zimmer Biomet Holdings, Inc. in an all-cash transaction plus contingent value rights (CVRs). Upon completion of the merger, Monogram's securities will be delisted from the Nasdaq.
🚩 Red Flags
- Delisting notice implied: Securities will be delisted from Nasdaq and deregistered upon completion of the merger.
📋 Key Facts
- Acquisition price for common stock: $4.04 per share in cash plus one CVR per share.
- Series D Preferred Stock consideration: $2.25 per share in cash.
- Series E Preferred Stock consideration: $100.00 per share in cash.
- CVR structure includes up to five milestones with potential payments of $1.04, $1.08, $3.41, $3.41, and $3.43 per CVR.
- The merger is subject to stockholder approval and regulatory/antitrust clearances (HSR Act).
- Termination fee: $11 million if the Company enters a deal with a third party for a 'Superior Offer'.
- Expected end date for closing: January 11, 2026 (extendable to April 11, 2026).
Monogram Technologies Inc. has triggered a mandatory conversion of its 8.00% Series D Convertible Cumulative Preferred Stock into common stock. This action was prompted by the company's common stock closing at or above $2.8125 per share for ten consecutive trading days.
🚩 Red Flags
- Potential dilution for existing common shareholders as preferred shares convert into new common equity.
📋 Key Facts
- Mandatory Conversion Notice Date: July 7, 2025
- Effective date of conversion: July 14, 2025
- Conversion Trigger: Common stock price closed at or above $2.8125 for 10 consecutive trading days.
- Security being converted: 8.00% Series D Convertible Cumulative Preferred Stock (each share converts to one share of common stock).
- The conversion was triggered under Section 6(a) of the Certificate of Designation.
Monogram Technologies Inc. announced that it has received regulatory approval from India’s Central Drugs Standard Control Organization to conduct clinical trials in India.
🚩 Red Flags
- Forward-looking statement warnings mention 'lack of profitability and need for additional capital to grow its business'.
📋 Key Facts
- Regulatory approval obtained from India's Central Drugs Standard Control Organization (CDSCO).
- Approval is specifically for the purpose of conducting clinical trials in India.
- The announcement was made via a press release on April 29, 2025.
Monogram Technologies Inc. announced that the U.S. FDA has granted 510(k) clearance for its mBôs™ TKA System. This regulatory milestone is a positive development for the company's product pipeline.
🚩 Red Flags
- Forward-looking statements warn of a lack of profitability and the need for additional capital to grow the business.
📋 Key Facts
- FDA granted 510(k) clearance for the mBôs™ TKA System on March 17, 2025.
- The announcement was made via press release under Item 7.01 (Regulation FD Disclosure).
- Company is an emerging growth company.
Monogram Technologies Inc. filed an amendment to its 8-K to issue a revised press release containing corrections to the balance sheets, statements of operations, and statements of cash flows for the period ended December 31, 2024.
🚩 Red Flags
- Restatement of previously issued financial information (via revised press release).
- Errors identified in the core financial statements (Balance Sheet, Income Statement, Cash Flow) for the most recent fiscal period.
- Risk factors mentioned include lack of profitability and need for additional capital.
📋 Key Facts
- The filing is an Amendment No. 1 (8-K/A) to a previously filed report.
- Corrections were made to the financial results for the period ending December 31, 2024.
- The corrections impact three primary financial statements: balance sheets, statements of operations, and statements of cash flows.
- The company is an emerging growth company.
Monogram Technologies Inc. filed an 8-K to furnish its earnings press release for the fiscal period ended December 31, 2024. The filing is a standard disclosure of quarterly financial results under General Instruction B.2.
🚩 Red Flags
- Forward-looking statements explicitly mention risks regarding lack of profitability and the need for additional capital to grow business.
📋 Key Facts
- Report date: March 12, 2025
- Reporting period end date: December 31, 2024
- The company issued an earnings press release (Exhibit 99.1)
- Company is classified as an 'emerging growth company'
Monogram Technologies Inc. issued a press release providing a regulatory update regarding its mBôs TKA System and clinical trial preparations in India.
🚩 Red Flags
- Forward-looking statements include risks related to lack of profitability and the need for additional capital to grow business.
📋 Key Facts
- The filing is a Regulation FD disclosure under Item 7.01.
- The company provided an update on the mBôs TKA System development.
- The update includes information regarding clinical trial preparation in India.
- The report was filed on February 25, 2025.
Monogram Technologies Inc. held its Annual Meeting of Stockholders on December 19, 2024. Shareholders approved the election of Class I directors, the appointment of Fruci & Associates II, PLLC as independent auditors, and amendments to the company's stock option plan.
🚩 Red Flags
- Relatively low approval margins for the stock option plan amendment (58.4%) and executive compensation (63.1%), suggesting potential shareholder dissatisfaction with dilution or pay structures.
📋 Key Facts
- Annual Meeting held on December 19, 2024, with 60% of Common Stock represented in person or by proxy.
- Class I directors Rick Van Kirk (73.1%) and Colleen Gray (74.3%) were elected to the Board until the 2027 annual meeting.
- Ratification of Fruci & Associates II, PLLC as independent registered public accounting firm for FY ending Dec 31, 2024, passed with 97.9% approval.
- Amendment to the Amended and Restated 2019 Stock Option and Grant Plan was approved (58.4% 'For').
- Compensation of named executive officers was approved on an advisory basis (63.1% 'For').
Monogram Technologies Inc. issued a Regulation FD disclosure regarding an update from the FDA concerning its 510(k) premarket filing for the mBôs TKA System following a Submission Issue Request meeting on December 17, 2024.
🚩 Red Flags
- Mention of 'lack of profitability and need for additional capital' in the cautionary note regarding forward-looking statements.
📋 Key Facts
- Meeting with the U.S. Food and Drug Administration (FDA) occurred on December 17, 2024.
- The meeting focused on a 'Submission Issue Request' regarding the company's 510(k) premarket filing for the mBôs TKA System.
- The filing is a Regulation FD disclosure intended to provide an update via press release (Exhibit 99.1).
Monogram Technologies Inc. announced that related parties, including CFO Noel Knape, purchased 480,767 shares of common stock for approximately $1 million on November 25, 2024.
🚩 Red Flags
- Related-party transactions with an executive officer (CFO) can sometimes indicate insider confidence or, conversely, a need for management to support the stock price through personal capital.
📋 Key Facts
- Related party transactions involving the purchase of company stock.
- CFO Noel Knape is specifically identified as a participant in the purchases.
- Total shares purchased: 480,767 common shares.
- Total transaction value: approximately $1 million.
- Transaction date: November 25, 2024.
Monogram Technologies Inc. issued an 8-K to announce its financial results and operational highlights for the three and nine months ended September 30, 2024. The company also scheduled a conference call for November 19, 2024, to discuss these results.
🚩 Red Flags
- Forward-looking statements highlight risks regarding lack of profitability and the need for additional capital to grow business.
📋 Key Facts
- Reported financial results for the three and nine months ended September 30, 2024.
- Provided operational highlights for the third quarter of 2024 via press release (Exhibit 99.1).
- Scheduled a conference call/Q&A session for Tuesday, November 19, 2024, at 4:30 pm ET.
Monogram Technologies Inc. issued an 8-K to announce that it has been named 'Orthopedic Joint Replacement Company of the Year 2024' by Medical Tech Outlook.
🚩 Red Flags
- The filing contains cautionary language regarding 'lack of profitability and need for additional capital to grow its business,' which is a standard risk disclosure but highlights the company's precarious financial position.
📋 Key Facts
- Announced award: Orthopedic Joint Replacement Company of the Year 2024.
- Awarding body: Medical Tech Outlook.
- Date of announcement: October 29, 2024.
Monogram Technologies Inc. issued a corrective press release to clarify an FDA Additional Information Request (AIR) regarding its mBôs TKA System submission. The clarification specifies that the company has 180 days from the receipt of the AIR to provide the requested information.
🚩 Red Flags
- Regulatory delay: An 'Additional Information Request' indicates that the initial submission was insufficient for immediate clearance, potentially delaying commercialization and revenue generation.
📋 Key Facts
- The filing corrects a previous press release issued on October 2, 2024.
- The FDA issued an Additional Information Request (AIR) for submission K242121 regarding the mBôs (Monogram mBôs TKA System).
- The company has exactly 180 days from the receipt of the AIR to respond to the FDA's request.
- No other changes were made to the previous disclosure beyond this timeline clarification.
Monogram Technologies closed a $11.7 million Series D Preferred Stock offering and simultaneously reported that the FDA has placed its mBôs TKA System application on hold following an Additional Information Request (AIR). The company must respond to the FDA within 180 days or risk withdrawal of the application.
🚩 Red Flags
- Regulatory setback: FDA placed a key product application on hold.
- Time-sensitive regulatory risk: 180-day deadline to prevent application withdrawal.
- Potential dilution: Issuance of over 5.7 million warrants and preferred shares.
- Cash burn/Capital need: The simultaneous closing of a $11.7M offering suggests an immediate need for liquidity.
📋 Key Facts
- Closed Series D Preferred Stock Offering on October 1, 2024.
- Sold 5,790,479 units consisting of one share of Series D Preferred Stock and one common stock purchase warrant per unit.
- Net proceeds from the offering were approximately $11.7 million.
- First dividend for Series D Preferred Stock is scheduled for October 15, 2024, at $0.033 per share.
- FDA issued an Additional Information Request (AIR) regarding submission K242121 (mBôs TKA System).
- The FDA application is currently on hold; the company has 180 days to respond before the application is considered withdrawn.
Monogram Technologies Inc. has declared a dividend of $0.0255 per share for its 8.00% Series D Convertible Cumulative Preferred Stock. The dividend will be paid in-kind based on the common stock's closing price from September 30, 2024.
🚩 Red Flags
- The company's cautionary note mentions 'risks inherent in the Company’s lack of profitability and need for additional capital to grow its business,' which is a standard but notable risk factor for micro-cap companies.
📋 Key Facts
- Dividend amount: $0.0255 per share of 8.00% Series D Convertible Cumulative Preferred Stock.
- Record date: Close of business on October 1, 2024.
- Payment method: Paid in-kind based on the closing price of common stock on September 30, 2024.
- Payment date: October 15, 2024.
Monogram Technologies Inc. has upsized its continuous offering of units from $10,000,000 to $12,500,000. The units consist of 8.00% Series D Convertible Cumulative Preferred Stock and one common stock purchase warrant.
🚩 Red Flags
- Continuous offering structure (often used by micro-caps for rapid capital raising).
- Convertible Preferred Stock and warrants can lead to significant dilution of existing common shareholders upon conversion/exercise.
📋 Key Facts
- Upsized continuous offering from $10,000,000 to $12,500,000 in units.
- Units include: (a) one share of 8.00% Series D Convertible Cumulative Preferred Stock and (b) one common stock purchase warrant.
- The offering is expected to stop taking subscriptions at midnight PT on September 12, 2024.
- Amendment No. 1 to the Prospectus Supplement dated July 9, 2024 was filed in connection with this increase.
Monogram Technologies Inc. announced its plan to close a Series D Preferred Stock continuous offering on September 12, 2024.
🚩 Red Flags
- Continuous offerings can lead to significant shareholder dilution in micro-cap companies.
📋 Key Facts
- The company plans to close the Series D Preferred Stock continuous offering on September 12, 2024.
- The filing is an announcement of a planned closing for a specific series of preferred stock.
Monogram Technologies Inc. announced a strategic collaboration with Shalby Limited via a press release on August 12, 2024.
📋 Key Facts
- The company entered into a strategic collaboration with Shalby Limited.
- The announcement was made via a press release issued on August 12, 2024.
- The filing is under Item 7.01 (Regulation FD Disclosure) and does not constitute 'filed' information for the purpose of the Exchange Act.
Monogram Technologies Inc. issued a press release announcing the submission of a 501(k) premarket filing to the FDA for its mBôs TKA System. This is a regulatory development regarding their medical device technology.
📋 Key Facts
- On August 8, 2024, the Company submitted a 501(k) premarket filing to the U.S. Food and Drug Administration (FDA).
- The filing is specifically for the company's mBôs TKA System.
- The disclosure was made via Item 7.01 (Regulation FD Disclosure).
Monogram Technologies Inc. entered into an At-the-Market (ATM) equity offering agreement with B. Riley Securities, Inc. on July 22, 2024. This allows the company to sell common stock from time to time through various trading markets to raise capital.
🚩 Red Flags
- Potential for immediate share dilution as the company may sell shares at market prices on an ongoing basis.
- ATM offerings are often used by micro-cap companies to raise quick liquidity, which can signal a need for cash to fund operations or debt obligations.
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement with B. Riley Securities, Inc. on July 22, 2024.
- The agreement enables the sale of shares under a previously declared S-3 shelf registration statement (File No. 333-279927).
- B. Riley Securities will act as the Sales Agent for the equity offering program.
- The company agreed to pay a commission of up to 3.0% of gross proceeds from the sales.
- The agreement can be terminated by either party with five days' prior notice.
Monogram Technologies Inc. entered into a selling agency agreement with Digital Offering LLC to facilitate a 'best efforts' offering of up to 4,444,445 units consisting of 8.00% Series D Convertible Cumulative Preferred Stock and common stock purchase warrants.
🚩 Red Flags
- Dilutive offering: Issuance of a large number of convertible preferred shares and warrants will significantly dilute existing common shareholders.
- High-premium warrants: The 150% premium on the warrant exercise price ($3.375) suggests the current market price is significantly lower, indicating potential distress or heavy dilution to raise capital.
- Best efforts basis: The agent has no obligation to purchase any units, meaning the company's ability to raise this specific capital is not guaranteed.
📋 Key Facts
- Offering size: Up to 4,444,445 units (1 share of 8.00% Series D Preferred Stock + 1 Common Stock Warrant per unit).
- Warrant terms: Exercisable after 180 days from July 9, 2024; exercise price is $3.375 per share.
- Pricing premium: The warrant exercise price represents a 150% premium over the unit price.
- Selling agent commission: Digital Offering LLC to receive 5.8% of gross proceeds.
- Series D Preferred Stock characteristics: Perpetual, cumulative, and ranks senior to common stock in liquidation/dividends.
Monogram Orthopaedics Inc. has completed a corporate name change to Monogram Technologies Inc. via a short-form merger, effective May 15, 2024. The company also announced it has been granted access to the NVIDIA Corporation Developer Program.
📋 Key Facts
- Effective May 15, 2024, the company's name changed from Monogram Orthopaedics Inc. to Monogram Technologies Inc.
- The change was executed through a parent/subsidiary short-form merger with its wholly owned subsidiary, Monogram Technologies Inc.
- Stock ticker 'MGRM' on Nasdaq remains unchanged.
- No changes to headquarters, management, employees, assets, or liabilities resulted from the merger.
- The company was granted access to the NVIDIA Corporation Developer Program.
Monogram Orthopaedics Inc. issued an 8-K to announce its financial results and operational highlights for the three months ended March 31, 2024. The filing includes a press release (Exhibit 99.1) and schedules a conference call for May 22, 2024.
🚩 Red Flags
- Forward-looking statements explicitly mention 'lack of profitability' and the 'need for additional capital to grow its business'.
📋 Key Facts
- Reported financial results for the quarter ending March 31, 2024.
- Provided operational highlights via a press release dated May 14, 2024.
- Scheduled a conference call and Q&A session for Wednesday, May 22, 2024, at 4:30 pm ET.
Monogram Orthopaedics provided a regulatory update regarding its mBôs surgical system following discussions with the FDA. The company received feedback on its verification test plan and clinical trial protocol, which management believes will facilitate a successful 510(k) submission.
🚩 Red Flags
- The company explicitly mentions 'risks inherent in the Company's lack of profitability and need for additional capital to grow its business' in the cautionary note.
- Estimated $1.5M cost for clinical trials represents a significant cash outlay for a micro-cap company.
📋 Key Facts
- FDA provided written feedback on April 19, 2024, regarding a pre-submission request from February 9, 2024.
- The company held a follow-up teleconference with the FDA on April 24 to discuss the mBôs TKA System verification test plan and an Outside the U.S. (OUS) clinical trial protocol.
- Management assesses that the proposed testing plan is generally acceptable for addressing technical differences with the predicate device.
- The proposed OUS clinical trial would involve approximately 100 knee surgeries at three sites with three months of follow-up.
- Estimated cost to run the proposed OUS clinical trial is approximately $1.5 million.
- Management intends to run a clinical trial for post-launch marketing regardless of whether it is required for FDA clearance.
Monogram Orthopaedics provided an update regarding its existing equity financing agreement with B. Riley Principal Capital II and a post-effective amendment to its Form S-1 registration statement. The company also reported being disqualified from the NVIDIA Inception Program due to its status as a public entity.
🚩 Red Flags
- Ongoing dilution via an equity line/purchase agreement with B. Riley Principal Capital II.
- Significant amount of shares (over 6 million) registered for resale, which can create downward pressure on stock price.
📋 Key Facts
- The Company has an agreement with B. Riley Principal Capital II to sell up to $20,000,000 or 5,847,725 shares (19.99% cap) of common stock.
- As of April 18, 2024, the Company has issued 256,026 shares for gross proceeds of $887,831.
- The Company filed a Post-Effective Amendment to Form S-1 registering up to 6,243,974 shares for resale.
- The Company was denied entry into the NVIDIA Corporation Inception Program because it is already a publicly traded company.
Monogram Orthopaedics Inc. released an investor presentation containing financial and operational results for the fiscal year ended December 31, 2023, and year-to-date operating information.
📋 Key Facts
- Filing date: March 21, 2024
- Content: Investor presentation including FY2023 financial/operational results and YTD operating info
- The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) and not 'filed' for liability purposes under Section 18.
Monogram Orthopaedics Inc. announced the effective filing of its Sixth Amended and Restated Certificate of Incorporation as of March 14, 2024. The amendment simplifies the company's capital structure by eliminating multiple series of preferred stock and establishes a classified board of directors.
📋 Key Facts
- Effective date of the Sixth Amended and Restated Certificate of Incorporation: March 14, 2024.
- Eliminated all Series A, Series B, and Series C classes of Preferred Stock.
- Authorized a single class of Preferred Stock consisting of 60,000,000 shares.
- Established a classified board of directors with three classes and staggered terms.
Monogram Orthopaedics Inc. filed an 8-K to furnish its earnings press release for the fiscal period ended December 31, 2023.
📋 Key Facts
- The filing is a routine disclosure of financial results under Item 2.02.
- Reporting period: Fiscal year/period ended December 31, 2023.
- Filing date: March 15, 2024.
- Includes Exhibit 99.1 (Earnings Press Release).